Halozyme scores $63M drug delivery deal

Halozyme has inked another pact for rHuPH20, an enzyme designed to spur the absorption of certain injectables. This $63 million deal--$9 million upfront and $54 million in milestones--gives Intrexon the right to use the enzyme technology with its therapy for a rare genetic disorder. Halozyme inked a similar $83 million deal last month with ViroPharma. "The combination of Intrexon's synthetic DNA platform for high-level A1AT production with Halozyme's subcutaneous enzyme technology may enable the first recombinant human A1AT replacement therapy with a more patient-friendly administration profile," said Halozyme CEO Gregory Frost. Release

Suggested Articles

Johnson & Johnson is joining the growing ranks of biopharmas in working on a new vaccine for the coronavirus out of China.

Allergan is returning rights to brazikumab but funding the cost of development in Crohn’s disease and ulcerative colitis.

Quench Bio is going after a family of proteins involved in inflammatory cell death to treat inflammatory diseases in a more holistic way.